Inspra (Eplerenone)

Eplerenone selectively blocks the mineralocorticoid (aldosterone) receptor in the kidney’s distal tubules. By inhibiting aldosterone binding, it reduces sodium reabsorption and potassium excretion, leading to decreased fluid volume, lower blood pressure, and attenuation of pathological cardiac remodeling in heart‑failure states.

The dosage of Inspra is individualized by the prescribing clinician based on the patient’s condition, renal function, and serum potassium levels. The prescriber determines the appropriate starting dose and any subsequent titration, following current clinical guidelines and laboratory monitoring.

Safety of eplerenone in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Inspra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The team then replies with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Both eplerenone (Inspra) and spironolactone are aldosterone antagonists, but eplerenone is more selective for the mineralocorticoid receptor, resulting in fewer anti‑androgenic side effects such as gynecomastia. Spironolactone may have a broader hormonal profile, which can be advantageous in certain conditions but may increase the risk of hormonal adverse events.

Inspra tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, excessive heat and direct sunlight to maintain potency throughout its shelf life.

Inspra is taken orally, usually once daily. It can be swallowed with or without food, but patients should follow the specific instructions provided by their prescriber and avoid crushing or chewing the tablet unless directed otherwise.

The most serious risks include severe hyperkalaemia, which can cause cardiac arrhythmias, and acute renal impairment, especially in patients with pre‑existing kidney disease. Rare but serious reactions such as angioedema and significant hepatic dysfunction may also occur and require immediate medical attention.

Inspra is contraindicated in patients with known hypersensitivity to eplerenone, those with serum potassium levels above 5.0 mmol/L, and individuals with severe renal impairment (eGFR <30 mL/min/1.73 m²). Caution is also advised for patients taking other potassium‑raising agents.